Informed Decisions………. Better Health Outcomes
The Center for Drug Policy and Technology Assessment (CDPTA) is a pioneering regional center providing hospital-based health technology assessment (HB-HTA) services, drug information, and pharmacovigilance services. CDPTA specializes in conducting economic evaluation assessments and Decision Analytical Modeling (DAM).
Meanwhile, Health Technology Assessment (HTA) is a “multidisciplinary process that uses explicit methods to determine the value of health technology at different points in its lifecycle. It aims to inform decision-making and promote an equitable, efficient, high-quality health system”.
The CDPTA generates (HB-HTA) reports which include an assessment of the clinical effectiveness/ efficacy evidence, safety evidence, quality of life evidence, and economic evidence.
To improve a rational selection and use of health technologies through applying HTA to generate evidence-based information to policymakers, health care providers, and patients, and maintain HTA capacity building within the Center.
To become a leading regional center providing HTA and drug information services recommendations to improve health outcomes.
CDPTA Core Values
- Continuous learning
- Innovation and creativity
Health Technology Assessment Fellowship Program (HTA-FB)
The HTA Fellowship Program (HTA-FP) aims to build capacities for conducting health technology assessments and health economics. The program provides fellows with individualized post-graduate training to become independent HTA researchers.
For further information about HTA-FP, please refer to the published article entitled: “A capacity-building programme in health technology assessment for hospital pharmacists in a low- to middle-income country”.
- Abeer A. Al-Rabayah, BSc Pharm, MBA, MSc (iHTA), PMP, Head, Center for Drug Policy and Technology Assessment
- Rawan F. Alfroukh, Pharm.D, BCPS, MSc (Health Econ)
- Razan Sawalha, BS Pharm, MSc (Health Econ)
- Maha Dalbah, Pharm.D. BCOP
- Khader Habash, Pharm.D